Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats

Basit Öğe Kaydı
dc.contributor.authorDemirtas, A.
dc.contributor.authorAzboy, I.
dc.contributor.authorBulut, M.
dc.contributor.authorUcar, B. Y.
dc.contributor.authorAlabalik, U.
dc.contributor.authorNecmioglu, N. S.
dc.date.accessioned2024-04-24T17:37:34Z
dc.date.available2024-04-24T17:37:34Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND: Today, there is a small number of studies on the effects of Enoxaparin and Fondaparinux used commonly in the prevention of venous thromboembolism on healing of fracture cases. AIM: The aim of this study was to investigate clinically, radiologically and histopathologically, the effects of Enoxaparin, Fondaparinux and Ri-varoxaban used in thromboembolism prophylaxis on fracture healing in a rat model of femur fracture. MATERIALS AND METHODS: Thirty-two male Sprague Dawley rats were randomized into four groups (n=8): the control group (Group 1), the Enoxaparin group (Group 2), the Fondaparinux group (Group 3), and Rivaroxaban group (Group 4). Under general anesthesia, a standard closed fracture was created in the left femur of each rat using an osteotome. Group 1 was given saline solution (1 cc/day, sc), Group 2 Enoxaparin (100 anti Xa IU/kg/day, sc), Group 3 Fondaparinux (0.2 mg/kg/day, sc), and Group 4 Rivaroxaban (3 mg/kg/day, po) for 21 days. After all rats were sacrificed at the end of day 21, their left femurs were disarticulated at the level of the hip and knee. The bony union was radiologically, clinically, and histopathologically evaluated. RESULTS: No differences were found between the groups in terms of clinical, radiological, and histopathological findings in fracture healing (p = 0.849, p = 0.731, and p = 0.395, respectively). CONCLUSIONS: Enoxaparin, Fondaparinux and Rivaroxaban used in thromboembolism prophylaxis cause no significant changes in fracture healing with short term follow up. Thus, they can be safely used in cases of fractures.en_US
dc.identifier.endpage1856en_US
dc.identifier.issn1128-3602
dc.identifier.issue14en_US
dc.identifier.pmid23877846
dc.identifier.scopus2-s2.0-84884192899
dc.identifier.scopusqualityQ2
dc.identifier.startpage1850en_US
dc.identifier.urihttps://hdl.handle.net/11468/21040
dc.identifier.volume17en_US
dc.identifier.wosWOS:000325203900002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectThromboembolismen_US
dc.subjectFracture Healingen_US
dc.subjectEnoxaparinen_US
dc.subjectFondaparinuxen_US
dc.subjectRivaroxabanen_US
dc.titleInvestigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in ratsen_US
dc.titleInvestigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu